PLLA-LASYNPRO™ Injections for Skin Laxity Treatment (Juläine)
Evaluation of Histological Outcomes Following Poly-L-lactic Acid (PLLA) LASYNPRO™ Injections for Skin Laxity Treatment in Patients Requiring Post Bariatric Surgery: A Proof-of-Concept Clinical Study
This single-center, open-label, intra-subject controlled proof-of-concept clinical study will evaluate the histological and clinical effects of Poly-L-lactic Acid (PLLA) LASYNPRO™ (Juläine) injections for treatment of skin laxity in patients requiring post-bariatric surgery. Fifteen participants will be enrolled. Each participant will serve as his or her own control, with one thigh treated with PLLA LASYNPRO™ and the contralateral thigh left untreated.
Participants will receive 3 injections in the treated thigh over approximately 3 months, followed by planned post-bariatric plastic surgery at 3, 6, or 9 months after the last injection, depending on assigned group. During surgery, tissue samples from treated and untreated areas will be collected for histological evaluation. A follow-up visit will occur approximately 30 days after surgery.
The primary endpoint is comparison of collagen type I and collagen type III between treated and untreated areas. Secondary endpoints include histological comparison of elastic fibers, stromal cell populations, inflammatory biomarkers, cell proliferation markers, and assessment of stretch marks, as well as safety. An exploratory endpoint is assessment of post-operative scar healing.
Przegląd badań
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: A.Piovani (Evidence Generation Project Manager)
- Numer telefonu: +39 0249530047
- E-mail: arianna.piovani@evidilya.com
Lokalizacje studiów
-
-
-
Siena, Włochy
- Rekrutacyjny
- Azienda Ospedaliero Universitaria Senese
-
Kontakt:
- R.Cuomo
- E-mail: roberto.cuomo2@unisi.it
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Male or female aged ≤ 60 years
- Previous bariatric surgery (one anastomosis gastric bypass)
- Stable weight for at least 6 months prior to baseline
- Post-weight loss skin laxity and ptosis requiring surgery
- ΔBMI ≥ 7 defined as the change in BMI from scheduled bariatric surgery to baseline
- BMI ≤ 30
- Pittsburgh scale rating ≥10
- Ability to give written informed consent
- Willing to participate in the study and attending the visits
Exclusion Criteria:
- Skin infection or skin inflammation status
- Acute or chronic skin disease
- ΔBMI < 7 defined as the change in BMI from scheduled bariatric surgery to baseline
- BMI > 30
- Male or female aged 60 > years
- Pregnancy and lactating; if a female is of childbearing potential, she should have a negative pregnancy test and should use a highly effective method to avoid pregnancy for the duration of the trial
- Any clinically significant findings, as determined by the investigator, from laboratory tests and individual patient's medical history, that may contraindicate post-bariatric surgery for the patient
- History of allergies to any of the constituents of the product
- Haemorrhagic disease or under anticoagulant therapy
- Have a known history of or susceptibility to keloid formation or hypertrophic scarring
- Immune deficiencies
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Treated thigh
PLLA injection
|
Three injections
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
The primary objective of the study is to evaluate the histological effects of PLLA LASYNPRO™ JULÄINE injections in the cutaneous tissue of patients requiring post-bariatric surgery for skin laxity.
Ramy czasowe: Group 1 (6 months from baseline visit), Group 2 (9 months from baseline visit), Group 3 (12 months from baseline visit)
|
Comparison of collagen type I and type III between treated and not treated areas
|
Group 1 (6 months from baseline visit), Group 2 (9 months from baseline visit), Group 3 (12 months from baseline visit)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Density of elastic fibres in JULÄINE treated vs non-treated areas
Ramy czasowe: Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
Histological evaluation and comparison between JULÄINE treated and non-treated areas of: Density of elastic fibres (Massons's trichrome staining and Van Gieson staining for elastic fibres). Unit of Measure: % stained Area |
Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
|
Percentage of fragmented elastic fibres (elastolysis) in JULÄINE treated vs non-treated areas
Ramy czasowe: Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
Histological evaluation and comparison between JULÄINE treated and non-treated areas of: -Presence and percentage of fragmented elastic fibres (elastolysis): quantitative count of the area occupied by elastic fibres as well as the number of intact and fragmented fibres. Unit of Measure:% of Total Fibers |
Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
|
Stromal cell population in JULÄINE treated vs non-treated areas
Ramy czasowe: Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
Histological evaluation and comparison between JULÄINE treated and non-treated areas of: -Stromal cell population evaluated as the percentage of single cell populations/mm2. Unit of Measure: percentage of single cell populations per mm². |
Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
|
Presence of Demodex in JULÄINE treated vs non-treated areas
Ramy czasowe: Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
Presence of etiological agents related to inflammation (PAS: Demodex) Unit of Measure: Positive/negative
|
Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
|
Presence of etiological agents of inflammation (CD68, CD3, CD20) in JULÄINE treated vs non-treated areas
Ramy czasowe: Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
Histological evaluation and comparison between JULÄINE treated and non-treated areas of: -Presence of following antibodies: CD68 (macrophages); CD3 and CD20 (lymphocytes). Unit of Measure: Cells count/ mm2 |
Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
|
Presence of etiological agents of inflammation ( Vimentin, CD34,) in JULÄINE treated vs non-treated areas
Ramy czasowe: Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
-Presence of the following antibodies: Vimentin and CD34 (stroma) Unit of Measure: %
|
Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
|
Presence of Ki-67 as marker of cell proliferation in JULÄINE-treated and non-treated areas
Ramy czasowe: Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
Presence of Ki-67 as marker of cell proliferation.
Unit of measure: percentage of Ki-67-positive cells (%)
|
Group 1 ( 6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
|
Presence of fibrilline, elastine, emilin-1 and collagen type IV and VII in JULÄINE vs non-treated areas
Ramy czasowe: Group 1 (6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
Histological evaluation and comparison between JULÄINE treated and non-treated areas of:
|
Group 1 (6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
|
Other inflammatory biomarkers (CD80, CD86, CD40, MHC-II, TLR4; CD11b+, CD14+, TNF-α if inflammatory status) in JULÄINE vs non-treated areas
Ramy czasowe: Group 1 (6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
Histological evaluation and comparison between JULÄINE treated and non-treated areas of: -Other inflammatory biomarkers such as: CD80 (B7-1), CD86 (B7-2), CD40, MHC-II, TLR4 and in case of an inflammatory status also: CD11b+ CD14+, and TNF-α. Unit of Measure: Cells count/ mm2 for each biomarker |
Group 1 (6 months from baseline), Group 2 (9 months from baseline), Group 3 (12 months from baseline)
|
|
Investigator-rated improvement of atrophic skin changes in proximity to stretch marks in the JULÄINE-treated thigh compared to baseline, assessed on standardised photographs using a 5-point Global Aesthetic Improvement scale (-1 to +3)
Ramy czasowe: Through study completion, an average of 1 year
|
Standardised digital photographs of the JULÄINE-treated thigh are acquired from baseline (Visit 1, before the first injection) through to the end of the study.
The investigator compares baseline vs post-treatment photographs side-by-side and rates the change in atrophic skin changes in proximity to stretch marks on a 5-point Global Aesthetic Improvement scale: -1 = worsened (deterioration vs baseline); 0 = no change; +1 = slight improvement; +2 = moderate improvement; +3 = marked improvement.
Subjects with no visible stretch marks or atrophic skin changes in the treated area at baseline are classified as Not Applicable and excluded from the analysis.
|
Through study completion, an average of 1 year
|
|
Evaluation of safety of PLLA LASYNPRO™ JULÄINE
Ramy czasowe: Through study completion, an average of 1 year
|
Safety (AEs, SAEs, SADEs)
|
Through study completion, an average of 1 year
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of subjects by post-operative wound appearance category (well healed / mild inflammation / dehiscence / infection / other) in the JULÄINE-treated thigh compared to the untreated thigh, assessed on physical examination
Ramy czasowe: 30 days from post-bariatric surgery for each group
|
At the follow-up visit (Visit 5, 30 days after post-bariatric surgery and biopsy) the investigator performs a physical examination of the surgical wound on both the JULÄINE-treated thigh and the contralateral untreated thigh (intra-subject control).
Wound appearance is classified by the investigator into one of the following categories: well healed, mild inflammation, dehiscence, infection, or other (specified).
The outcome is reported as the number and proportion of subjects in each wound-appearance category, separately for the treated thigh and the untreated thigh.
|
30 days from post-bariatric surgery for each group
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: R. Cuomo, Azienda Ospedaliera Universitaria Senese
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- NORD0001
- CIV-IT-25-10-054855 (Inny identyfikator: Eudamed)
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .